Inhibikase Therapeutics

Inhibikase Therapeutics, Inc. provides infectious disease treatments. It develops small molecule platform for treating both bacterial and viral infectious diseases. It operates through RAMP™ Drug Innovation Engine technology. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inhibikase Therapeutics advances trials amidst safety concerns and financial stability

Inhibikase Therapeutics made progress in trials but faces safety concerns and financial challenges.
Opportunities lie in advancing Phase III plans and clinical development for potential market growth.
The company's near-term milestones and financial stability are key areas to watch for future performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.

BOSTON and ATLANTA , Nov. 7, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that the Company was informed via e-mail communication that the U.S. Food and Drug Administration (FDA) has reviewed its Investigational New Drug (IND) application for IkT-148009 for the treatment of Multiple Systems Atrophy (MSA) and has  issued a Clinical Hold on the IkT-148009 201 program in Parkinson's disease (PD) and the use of IkT-148009 in MSA. The FDA indicated it will provide an official clinical hold letter to Inhibikase within 30 days.

Inhibikase Therapeutics Announces FDA Clinical Hold on IkT-148009 Programs

BOSTON and ATLANTA , Oct. 12, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that Milton Werner, Ph.D., President and Chief Executive Officer of Inhibikase, will present at the Cambridge Healthtech Institute's Inaugural Neurodegeneration Targets: Drug Discovery for Brain and Nerve-Related Progressive Disorders Conference.

Inhibikase Therapeutics to Present at the Cambridge Healthtech Institute's Inaugural Neurodegeneration Targets Conference

BOSTON and ATLANTA , Sept. 21, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that Milton Werner, Ph.D.

Inhibikase Therapeutics to Present at the Grand Challenges in Parkinson's Disease Conference

IkT-148009 was well-tolerated with high systemic exposure and persistent penetration into the central nervous system (CNS) in older and elderly healthy volunteers and Parkinson's patients No clinically significant adverse events observed Actively enrolling Phase 2a '201' clinical trial of IkT-148009 in patients with untreated Parkinson's disease BOSTON and ATLANTA , Sept. 15, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will present safety, tolerability, pharmacokinetics and exploratory Parkinson's assessment data from the Company's Phase 1/1b '101' study of IkT-148009 in Parkinson's disease at the International Congress of Parkinson's Disease and Movement Disorders tomorrow, September 16 th, 2022.

Inhibikase Therapeutics to Present Data from Phase 1/1b study of IkT-148009 at the Movement Disorders Society Congress

BOSTON and ATLANTA , Sept. 1, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders as well as other diseases arising from protein kinases, today announced the appointment of Ms.

Inhibikase Therapeutics Appoints Gisele Dion to Board of Directors

BOSTON and ATLANTA, Aug. 26, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that the U.S. Food and Drug Administration (FDA) has reviewed its Investigational New Drug (IND) application for IkT-001Pro for the treatment of Chronic Myelogenous Leukemia (CML) and issued a Study May Procced (SMP) letter. IkT-001Pro is a prodrug formulation of imatinib mesylate and has been developed to improve the safety of the first FDA-approved Abelson (Abl) kinase inhibitor, imatinib (marketed as Gleevec®).

Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia

BOSTON and ATLANTA , Aug. 23, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced dosing of the first patient in its Phase 2a study ('201 trial') evaluating IkT-148009, the Company's novel Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson's disease. "Dosing of the first patient in our Phase 2a '201' trial represents a major milestone in the development of IkT-148009 for the treatment of Parkinson's disease and related disorders," commented Milton H.

Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease

Inhibikase Therapeutics, Inc. (NASDAQ:IKT ) Q2 2022 Earnings Conference Call August 15, 2022 8:00 AM ET CompanyParticipants Milton Werner - CEO Joseph Frattaroli - CFO Alex Lobo - Stern IR Conference Call Participants Danya Ben-Hail - JonesTrading Operator Good day, and welcome to Inhibikase Therapeutics' Second Quarter 2022 Financial Results Conference Call. All participants are in listen-only mode.

Inhibikase Therapeutics, Inc. (IKT) CEO Milton Werner on Q2 2022 Results - Earnings Call Transcript

Company to host conference call and webcast on Monday, August 15, 2022, at 8:00am ET BOSTON and ATLANTA , Aug. 12, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics with the potential to modify the course of Parkinson's disease ("PD") and related disorders, today reported financial results for the second quarter ended June 30, 2022 and highlighted recent developments. "In the second quarter, we continued to make progress across our entire portfolio.

Inhibikase Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity

BOSTON and ATLANTA , Aug. 8, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that it will report financial results for the second quarter ended June 30, 2022 on Friday, August 12, 2022, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m.

Inhibikase Therapeutics to Report Second Quarter 2022 Financial Results on August 12, 2022

Phase 1/1b '101' study terminated early; demonstrated favorable safety, tolerability, and pharmacokinetic profile in single doses up to 325 mg and multiple doses up to 100 mg Phase 2a '201' study open for enrollment; expect to dose first patient in 2Q 2022 Phase 1/1b trial results to be presented at the Movement Disorders Society Congress in Madrid, Spain September, 2022 BOSTON and ATLANTA , June 13, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that it is advancing its Phase 2a study ('201 trial') following review of the study protocol and Phase 1/1b ('101 trial') data by the U.S. Food and Drug Administration (FDA or 'the Agency'). The 101 trial was a single and multiple ascending dose safety, tolerability and pharmacokinetics (PK) trial evaluating once daily administration of IkT-148009, the Company's lead c-Abl inhibitor for the treatment of Parkinson's disease.

Inhibikase Therapeutics Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review

Inhibikase Therapeutics, Inc. (NASDAQ:IKT ) Q1 2022 Earnings Conference Call May 17, 2022 8:00 AM ET Company Participants Alex Lobo - Stern Investor Relations Milton Werner - Chief Executive Officer Joseph Frattaroli - Chief Financial Officer Conference Call Participants Operator Greetings, welcome to Inhibikase Therapeutics' First Quarter 2022 Financial Results Conference Call. At this time, all participants are in listen-only mode.

Inhibikase Therapeutics, Inc. (IKT) CEO Milton Werner on Q1 2022 Results - Earnings Call Transcript

Company to host conference call and webcast on Tuesday, May 17, 2022, at 8:00am ET BOSTON and ATLANTA , May 16, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today reported financial results for the first quarter ended March 31, 2022 and highlighted recent developments. "As we kicked off 2022, we have worked diligently to advance our clinical and preclinical programs as well as extend our thought leadership in Parkinson's disease.

Inhibikase Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity

BOSTON and ATLANTA , May 10, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that Dr. Milton Werner, Ph.D., the Company's President & Chief Executive Officer will present at the upcoming H.C.

Inhibikase Therapeutics to Participate at the H.C. Wainwright Global Investment Conference

BOSTON and ATLANTA , May 9, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that it will report financial results for the first quarter ended March 31, 2022 on Monday, May 16, 2022, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m.

Inhibikase Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022

BOSTON and ATLANTA , April 21, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that Dr. Milton Werner, Ph.D., the Company's President & Chief Executive Officer will participate in a fireside chat at the B.

Inhibikase Therapeutics to Participate at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference

BOSTON and ATLANTA , April 6, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that it will host a virtual KOL investor event on Wednesday, April 20, 2022 at 10:00 am ET. The virtual event will feature presentations and an interactive Q&A session from the Company's executive leadership team as well as key opinion leaders, Dr. Robert F.

Inhibikase Therapeutics to Host Virtual KOL Investor Event on April 20, 2022

Werner Enterprises

Inhibikase Therapeutics, Inc. (IKT) CEO Dr. Milton Werner on Q4 2021 Results - Earnings Call Transcript

BOSTON and ATLANTA , March 31, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today reported financial results for the full year ended December 31, 2021 and highlighted recent developments. "2021 was an important year for Inhibikase as we advanced our lead program IkT-148009 for Parkinson's disease into the clinic, continued to develop our early-stage pipeline programs and strengthened our balance sheet to support our development efforts well into 2023," commented Dr. Milton H.

Inhibikase Therapeutics Reports Full Year 2021 Financial Results and Highlights Recent Period Activity

BOSTON and ATLANTA , March 28, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that Dr. Milton Werner, Ph.D., the Company's President & Chief Executive Officer will give an oral presentation in the Next Generation Kinase Inhibitors Summit, being held from March 29-31, 2022.

Inhibikase Therapeutics to Participate in the Next Generation Kinase Inhibitors Summit

BOSTON and ATLANTA, Mar. 25, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that it will report financial results for the full year ended December 31, 2021 on Thursday, March 31, 2022, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m.

Inhibikase Therapeutics to Report Full Year 2021 Financial Results on March 31, 2022

BOSTON and ATLANTA , March 23, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that Dr. Milton Werner, Ph.D., the Company's President & Chief Executive Officer will present in the Maxim Group 2022 Virtual Growth Conference, being held from March 28 th through 30th.

Inhibikase Therapeutics to Participate in the Maxim Group 2022 Virtual Growth Conference

BOSTON and ATLANTA, March 8, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that Dr. Milton Werner, Ph.D., President & Chief Executive Officer of Inhibikase, will give an oral presentation at the AD/PD™, Alzheimer's & Parkinson's Diseases Conference being held in Barcelona, Spain from March 15-20, 2022.

Inhibikase Therapeutics to Present Phase 1/1b Clinical Data at the Upcoming AD/PD™ Alzheimer's & Parkinson's Diseases Conference

BOSTON and ATLANTA, Jan. 5, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today highlighted recent developments and anticipated milestones for 2022. Key Business and Clinical milestones expected in 2022: Continue Phase 1 dose escalation of IkT-148009 in older and elderly healthy volunteers: IkT-148009 continues to be evaluated at higher single doses in older and elderly healthy volunteers as part of the Phase 1 study, which was initiated in February 2021.

Inhibikase Therapeutics Highlights 2022 Pipeline Goals and Milestones

The stock price of Inhibikase Therapeutics Inc (NASDAQ: IKT) increased by over 10% pre-market today. This is why it happened.

News for Inhibikase Therapeutics Stock (IKT)